{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:03:16Z","timestamp":1760853796050,"version":"3.37.3"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1124\/dmd.114.061937","type":"journal-article","created":{"date-parts":[[2014,12,31]],"date-time":"2014-12-31T05:10:46Z","timestamp":1420002646000},"page":"392-399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Conversions of Tricyclic Antidepressants and Antipsychotics with Selected P450s from Sorangium cellulosum So ce56"],"prefix":"10.1016","volume":"43","author":[{"given":"Martin","family":"Litzenburger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredy","family":"Kern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogan","family":"Khatri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.114.061937_bib1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.biotechadv.2008.07.005","article-title":"Cunninghamella\u2014a microbial model for drug metabolism studies\u2014a review","volume":"27","author":"Asha","year":"2009","journal-title":"Biotechnol Adv"},{"key":"10.1124\/dmd.114.061937_bib2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jbiotec.2006.01.026","article-title":"Cytochromes P450 as versatile biocatalysts","volume":"124","author":"Bernhardt","year":"2006","journal-title":"J Biotechnol"},{"key":"10.1124\/dmd.114.061937_bib3","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1007\/s00253-014-5767-7","article-title":"Cytochromes P450 as promising catalysts for biotechnological application: chances and limitations","volume":"98","author":"Bernhardt","year":"2014","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1124\/dmd.114.061937_bib4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cbpa.2013.01.028","article-title":"Engineering and application of P450 monooxygenases in pharmaceutical and metabolite synthesis","volume":"17","author":"Caswell","year":"2013","journal-title":"Curr Opin Chem Biol"},{"key":"10.1124\/dmd.114.061937_bib5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0300-483X(93)90062-W","article-title":"Human cell lines, derived from AHH-1 TK+\/- human lymphoblasts, genetically engineered for expression of cytochromes P450","volume":"82","author":"Crespi","year":"1993","journal-title":"Toxicology"},{"year":"2014","series-title":"D. G.. A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs","key":"10.1124\/dmd.114.061937_bib34"},{"key":"10.1124\/dmd.114.061937_bib6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/sj.bjp.0703540","article-title":"Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants","volume":"131","author":"Daniel","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.114.061937_bib7","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s002530051546","article-title":"Pharmaceutically active secondary metabolites of microorganisms","volume":"52","author":"Demain","year":"1999","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1124\/dmd.114.061937_bib8","first-page":"9","article-title":"[Modern drug development by molecular- and cell-biological methods]","volume":"18","author":"D\u00f6hmer","year":"2001","journal-title":"ALTEX"},{"key":"10.1124\/dmd.114.061937_bib9","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s12010-010-9100-3","article-title":"Convenient gram-scale metabolite synthesis by engineered fission yeast strains expressing functional human P450 systems","volume":"163","author":"Dr\u0103gan","year":"2011","journal-title":"Appl Biochem Biotechnol"},{"year":"2009","series-title":"ICH Guidance M3(R2) on Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorisation for Pharmaceuticals","key":"10.1124\/dmd.114.061937_bib10"},{"year":"2008","series-title":"Guidance for Industry: Safety Testing of Drug Metabolites","key":"10.1124\/dmd.114.061937_bib11"},{"key":"10.1124\/dmd.114.061937_bib12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/clpt.2009.283","article-title":"Metabolites in safety testing: \u201cMIST\u201d for the clinical pharmacologist","volume":"87","author":"Frederick","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.061937_bib13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0021-9673(01)86150-1","article-title":"A method for the determination of imipramine in human plasma by gas-liquid chromatography-mass fragmentography","volume":"74","author":"Frigerio","year":"1972","journal-title":"J Chromatogr A"},{"key":"10.1124\/dmd.114.061937_bib14","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/biot.201200187","article-title":"Production of human cytochrome P450 2D6 drug metabolites with recombinant microbes\u2014a comparative study","volume":"7","author":"Geier","year":"2012","journal-title":"Biotechnol J"},{"key":"10.1124\/dmd.114.061937_bib15","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1021\/tx7002849","article-title":"Engineering cytochrome p450 enzymes","volume":"21","author":"Gillam","year":"2008","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.114.061937_bib16","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00253-010-2472-z","article-title":"Characterization of the versatile monooxygenase CYP109B1 from Bacillus subtilis","volume":"87","author":"Girhard","year":"2010","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1124\/dmd.114.061937_bib17","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1021\/tx400449z","article-title":"Pragmatic approaches to determine the exposures of drug metabolites in preclinical and clinical subjects in the MIST evaluation of the clinical development phase","volume":"27","author":"Haglund","year":"2014","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.114.061937_bib18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2133\/dmpk.DMPK-13-RG-044","article-title":"In silico study on the inhibitory interaction of drugs with wild-type CYP2D6.1 and the natural variant CYP2D6.17","volume":"29","author":"Handa","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.114.061937_bib19","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.bbagen.2006.07.017","article-title":"Cytochrome P450 systems\u2014biological variations of electron transport chains","volume":"1770","author":"Hannemann","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/dmd.114.061937_bib20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cbpa.2008.01.029","article-title":"Heme-iron oxygenases: powerful industrial biocatalysts?","volume":"12","author":"Julsing","year":"2008","journal-title":"Curr Opin Chem Biol"},{"key":"10.1124\/dmd.114.061937_bib21","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.copbio.2011.02.008","article-title":"Cytochrome P450: taming a wild type enzyme","volume":"22","author":"Jung","year":"2011","journal-title":"Curr Opin Biotechnol"},{"key":"10.1124\/dmd.114.061937_bib22","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/0006-2952(94)90071-X","article-title":"Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation","volume":"47","author":"Kerr","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.114.061937_bib23","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00253-010-2756-3","article-title":"Regioselective hydroxylation of norisoprenoids by CYP109D1 from Sorangium cellulosum So ce56","volume":"88","author":"Khatri","year":"2010","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1124\/dmd.114.061937_bib24","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.chembiol.2010.10.010","article-title":"The CYPome of Sorangium cellulosum So ce56 and identification of CYP109D1 as a new fatty acid hydroxylase","volume":"17","author":"Khatri","year":"2010","journal-title":"Chem Biol"},{"key":"10.1124\/dmd.114.061937_bib25","first-page":"13104","article-title":"A natural heme-signature variant of CYP267A1 from Sorangium\u00a0cellulosum So ce56 executes diverse \u03c9-hydroxylation","volume":"10","author":"Khatri","year":"2014","journal-title":"FEBS J"},{"key":"10.1124\/dmd.114.061937_bib26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/bab.1087","article-title":"Novel family members of CYP109 from Sorangium cellulosum So ce56 exhibit characteristic biochemical and biophysical properties","volume":"60","author":"Khatri","year":"2013","journal-title":"Biotechnol Appl Biochem"},{"key":"10.1124\/dmd.114.061937_bib27","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/35051706","article-title":"Enzymes for chemical synthesis","volume":"409","author":"Koeller","year":"2001","journal-title":"Nature"},{"key":"10.1124\/dmd.114.061937_bib28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00253-011-3727-z","article-title":"CYP264B1 from Sorangium cellulosum So ce56: a fascinating norisoprenoid and sesquiterpene hydroxylase","volume":"95","author":"Ly","year":"2012","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1124\/dmd.114.061937_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10529-014-1653-8","article-title":"Drug metabolism in microorganisms","volume":"37","author":"Murphy","year":"2015","journal-title":"Biotechnol Lett"},{"key":"10.1124\/dmd.114.061937_bib30","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1211\/jpp.58.7.0001","article-title":"Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents","volume":"58","author":"Murray","year":"2006","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/dmd.114.061937_bib31","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/00008571-199610000-00009","article-title":"CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes","volume":"6","author":"Nakamura","year":"1996","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.114.061937_bib32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bbapap.2010.08.008","article-title":"Progress in tracing the evolutionary paths of cytochrome P450","volume":"1814","author":"Nelson","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/dmd.114.061937_bib33","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/S0022-3565(25)13120-0","article-title":"The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways","volume":"277","author":"Nielsen","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.114.061937_bib35","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0141-0229(02)00186-2","article-title":"Microbial\/enzymatic synthesis of chiral intermediates for pharmaceuticals","volume":"31","author":"Patel","year":"2002","journal-title":"Enzyme Microb Technol"},{"key":"10.1124\/dmd.114.061937_bib36","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1124\/dmd.30.11.1170","article-title":"Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites","volume":"30","author":"Pearce","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.061937_bib37","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0090-9556(25)06855-2","article-title":"Amitriptyline metabolites in human urine. Identification of phenols, dihydrodiols, glycols, and ketones","volume":"15","author":"Prox","year":"1987","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.061937_bib38","doi-asserted-by":"crossref","first-page":"7741","DOI":"10.1007\/s00253-012-4612-0","article-title":"Application of a new versatile electron transfer system for cytochrome P450-based Escherichia coli whole-cell bioconversions","volume":"97","author":"Ringle","year":"2013","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1124\/dmd.114.061937_bib39","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1074\/jbc.M511232200","article-title":"Crystal structure of human cytochrome P450 2D6","volume":"281","author":"Rowland","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.114.061937_bib40","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1248\/bpb.16.627","article-title":"Direct expression of adrenodoxin reductase in Escherichia coli and the functional characterization","volume":"16","author":"Sagara","year":"1993","journal-title":"Biol Pharm Bull"},{"key":"10.1124\/dmd.114.061937_bib41","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1248\/bpb.35.844","article-title":"Practical application of cytochrome P450","volume":"35","author":"Sakaki","year":"2012","journal-title":"Biol Pharm Bull"},{"key":"10.1124\/dmd.114.061937_bib42","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/cbic.201402443","article-title":"Characterization of the gene cluster CYP264B1-geoA from Sorangium cellulosum So ce56: Biosynthesis of (+)-eremophilene and its hydroxylation","volume":"16","author":"Schifrin","year":"2015","journal-title":"ChemBioChem"},{"key":"10.1124\/dmd.114.061937_bib43","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/nbt1354","article-title":"Complete genome sequence of the myxobacterium Sorangium cellulosum","volume":"25","author":"Schneiker","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1124\/dmd.114.061937_bib44","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0010-440X(99)90082-2","article-title":"A history of antipsychotic drug development","volume":"40","author":"Shen","year":"1999","journal-title":"Compr Psychiatry"},{"key":"10.1124\/dmd.114.061937_bib45","series-title":"The Prokaryotes","first-page":"31","article-title":"The myxobacteria","author":"Shimkets","year":"2006"},{"key":"10.1124\/dmd.114.061937_bib46","first-page":"1000126","article-title":"Comparative in-vitro intrinsic clearance of imipramine in multiple species liver microsomes: human, rat, mouse and dog","volume":"3","author":"Singh","year":"2012","journal-title":"Drug Metab Toxicol"},{"key":"10.1124\/dmd.114.061937_bib47","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1021\/cr9500500","article-title":"Heme-containing oxygenases","volume":"96","author":"Sono","year":"1996","journal-title":"Chem Rev"},{"key":"10.1124\/dmd.114.061937_bib48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1046\/j.1365-2710.1999.00200.x","article-title":"Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system","volume":"24","author":"Tanaka","year":"1999","journal-title":"J Clin Pharm Ther"},{"key":"10.1124\/dmd.114.061937_bib49","doi-asserted-by":"crossref","first-page":"22557","DOI":"10.1016\/S0021-9258(17)31682-4","article-title":"C-terminal region of adrenodoxin affects its structural integrity and determines differences in its electron transfer function to cytochrome P-450","volume":"269","author":"Uhlmann","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.114.061937_bib50","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/jps.2600670826","article-title":"Oxidative degradation of pharmaceutically important phenothiazines I: Isolation and identification of oxidation products of promethazine","volume":"67","author":"Underberg","year":"1978","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.114.061937_bib51","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.tibtech.2011.06.012","article-title":"Cytochrome P450 monooxygenases: an update on perspectives for synthetic application","volume":"30","author":"Urlacher","year":"2012","journal-title":"Trends Biotechnol"},{"key":"10.1124\/dmd.114.061937_bib52","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00253-003-1514-1","article-title":"Microbial P450 enzymes in biotechnology","volume":"64","author":"Urlacher","year":"2004","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1124\/dmd.114.061937_bib53","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1177\/00912700122012634","article-title":"Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies","volume":"41","author":"Venkatakrishnan","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.114.061937_bib54","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1039\/c001260m","article-title":"Myxobacterial secondary metabolites: bioactivities and modes-of-action","volume":"27","author":"Weissman","year":"2010","journal-title":"Nat Prod Rep"},{"key":"10.1124\/dmd.114.061937_bib55","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1039\/C1CS15192D","article-title":"P450(BM3) (CYP102A1): connecting the dots","volume":"41","author":"Whitehouse","year":"2012","journal-title":"Chem Soc Rev"},{"key":"10.1124\/dmd.114.061937_bib56","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.bcp.2010.06.045","article-title":"Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver\u2014A comparison with other phenothiazines","volume":"80","author":"W\u00f3jcikowski","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.114.061937_bib57","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/00004714-200112000-00002","article-title":"The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients","volume":"21","author":"Yokono","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"10.1124\/dmd.114.061937_bib58","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.tibtech.2007.05.003","article-title":"The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities","volume":"25","author":"Yun","year":"2007","journal-title":"Trends Biotechnol"},{"key":"10.1124\/dmd.114.061937_bib59","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.114.061937_bib60","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1146\/annurev.pa.33.040193.001143","article-title":"Recent studies on the structure and function of multisubstrate flavin-containing monooxygenases","volume":"33","author":"Ziegler","year":"1993","journal-title":"Annu Rev Pharmacol Toxicol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624104199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624104199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.114.061937","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:29:35Z","timestamp":1739906975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624104199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0090955624104199"],"URL":"https:\/\/doi.org\/10.1124\/dmd.114.061937","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Conversions of Tricyclic Antidepressants and Antipsychotics with Selected P450s from Sorangium cellulosum So ce56","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.114.061937","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}